{"id":"W2134091333","doi":"10.1186/1465-9921-12-156","title":"Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial","year":2011,"lang":"en","type":"article","venue":"Respiratory Research","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Tobacco Research Unit; University of Toronto","funders":"Novartis Pharma; GlaxoSmithKline; AstraZeneca","keywords":"Medicine; COPD; Placebo; Bronchodilator; Tiotropium bromide; Tolerability; Internal medicine; Vital capacity; Anesthesia; Ipratropium bromide; Randomized controlled trial; Spirometry; Asthma; Adverse effect; Lung; Lung function","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002125644,0.000232802,0.0004935215,0.0005087003,0.0002296515,0.00003281637,0.0004239651,0.0001455172,0.000421483],"category_scores_gemma":[0.0007652408,0.0001536439,0.00006533678,0.001189198,0.0008555331,0.0001555608,0.0004055327,0.000964565,0.0000732989],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004497093,"about_ca_system_score_gemma":0.00128668,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002306302,"about_ca_topic_score_gemma":0.00007303453,"domain_scores_codex":[0.9951598,0.0008892991,0.0005071983,0.0006465765,0.001948931,0.0008481751],"domain_scores_gemma":[0.997115,0.0005079719,0.00007472557,0.0009448212,0.0008282933,0.0005292441],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6116786,0.002379815,0.350578,0.0004836253,0.0001783739,0.0001727855,0.001394663,0.00003039154,0.0003221453,0.0005860981,0.001231801,0.03096371],"study_design_scores_gemma":[0.07974578,0.003376815,0.9122605,0.0002702183,0.00002359942,0.000002657643,0.0003366591,0.0001033624,0.0003925496,0.00007733766,0.00322848,0.0001820422],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875342,0.0004145155,0.00000561777,0.0001866203,0.0000436951,0.004301165,0.00005287803,0.00002074892,0.007440606],"genre_scores_gemma":[0.9990103,0.0000240772,0.00007888852,0.0001202545,0.0001207158,0.0001646241,0.00001078181,0.00005307807,0.0004172692],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5616825,"threshold_uncertainty_score":0.6265416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08327086123733947,"score_gpt":0.348145709231048,"score_spread":0.2648748479937085,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}